查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1677169

晕动病治疗市场按药物类型、治疗类型、剂型、通路和最终用户划分 - 2025 年至 2030 年全球预测

Motion Sickness Treatment Market by Type Of Drugs, Treatment Type, Dosage Forms, Distribution Channel, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

晕动病治疗市场预计在 2024 年达到 7.1969 亿美元，2025 年达到 7.4093 亿美元，到 2030 年将达到 8.6305 亿美元，复合年增长率为 3.07%。

主要市场统计数据
基准年 2024 年 7.1969亿美元
预计 2025 年 7.4093亿美元
预测年份 2030 8.6305亿美元
复合年增长率（%） 3.07%

晕动病长期以来一直是影响全球数百万人的难题，其治疗模式也发生了重大变化。本报告深入研究了不断发展的行业，重点介绍了当前的治疗方法和新兴趋势。随着研究的进步和消费者偏好的变化，人们重新关注的不仅是缓解症状，还增强患者的整体幸福感。

本介绍全面说明了创新治疗方法、先进配方和独特剂型如何重新定义患者照护。在平衡临床准确性和市场洞察力的同时，后续内容深入探讨产业转型、分析细分洞察、区域市场动态和关键公司策略。每个部分都经过了细緻的研究，为行业领导者和决策者提供了清晰、可行的蓝图，以驾驭竞争格局。

该分析基于严格的资料收集、专家访谈和当代市场动态，为读者提供了当前实践和未来方向的整体概况。透过强调传统治疗方案和最新创新，该报告鼓励相关人员考虑跨不同治疗方法和分销管道的综合方法。透过这样做，我们确保叙述不仅反映临床效果，还反映市场可行性和患者便利性。

影响晕动病治疗市场的不断变化的趋势

近年来，晕动病治疗领域发生了重大变化。科技进步不仅增强了诊断能力和穿戴式感测设备，也促成了创新药物输送系统的出现。这种转变正在推动市场从传统的治疗通讯协定转向更客製化、高效和以患者为中心的方法。

最显着的变化之一是数位健康技术的日益融合。数位治疗和即时监测对于评估患者对各种治疗方案的反应至关重要，从而可以实现更个人化的护理策略。药理学的创新导致了改良剂型的开发，从而提高了吸收率并最大限度地减少了副作用。在这种动态的背景下，传统治疗方法正在被安全性和有效性显着提高的现代治疗方法所补充，在某些情况下甚至被取代。

另一个变革趋势是消费行为的演变。知情的患者要求明确了解他们的治疗方案，从而推动公司采用创新和前瞻性的策略。治疗方法已发生明显转变，除了传统的非处方药和处方药外，还采用自然疗法。此外，市场进入策略越来越多地包括与科技公司建立策略合作伙伴关係，以开发应用程式和监控工具，扩大可获得的治疗见解和患者管理实践的范围。

这种不断发展的格局的特点是科学突破与市场观点的融合，并认识到综合医疗保健解决方案的重要性。随着从业者和投资者都在寻求永续成长的道路，该行业表现出临床研究和市场主导创新之间的密切相互作用。从改进的配方到先进的交付管道，采用整体治疗方法的动力凸显了当今市场的变革性质。

正在进行的争论不仅集中在个别治疗方法的有效性上，还集中在新技术和创新经营模式将如何定义晕动病治疗的未来。随着监管机构简化新产品和治疗通讯协定的审批，该行业将迎来前所未有的合作、审查和市场渗透水平。

晕动病治疗的全面细分见解

了解晕动病治疗市场的重点是其复杂的细分。透过分析该行业，我们发现市场研究非常细緻，首先是根据药品类型进行细分。本观点将考虑抗胆碱能药物和抗组织胺药物治疗方法，强调每种药物都提供了预防和缓解症状的不同机制。这些化合物的细微动态不仅可以作为临床实践的指导，还可以作为未来研究和开发的指标。

此外，根据治疗类型进行细分，市场分为自然疗法、非处方药和处方药。这种区分至关重要，因为它反映了不同地区不同的患者需求和监管环境。自然疗法由于其安全且没有副作用而越来越受欢迎。另一方面，处方药用于治疗更严重的病例，需要在疗效和安全性之间取得平衡。

分析将继续关注剂型，分为注射剂、口服剂型和经皮吸收贴片。每种剂型都与特定的患者群体或临床情况相关。注射剂通常用于治疗急性症状，而口服剂则方便定期使用。经皮贴片代表了一种现代药物输送方法，透过缓释性机制提供稳定的治疗水平，最大限度地提高疗效，同时最大限度地减少血浆浓度波动。

另一层细分则着重于分销管道，分为线上药局和零售药局。这种细分不仅反映了消费者购买行为的演变，也反映了数位转型在製药业日益增长的重要性。对数位平台的日益依赖凸显了电子商务在覆盖更广泛的患者群体和及时有效地提供治疗性介入的作用。

最后，根据诊所、居家医疗、医院等最终用户进行的细分清楚地说明了市场的多面性。诊所通常充当初步诊断和治疗中心，而居家照护解决方案为慢性或不太严重的疾病提供便利。医院表明需要进行重大而紧急的护理，并且通常采用更有条理的管理和监控方法。这些差异化细分市场提供的多层次洞察创建了一个对于策略规划和市场定位至关重要的综合框架。

了解这些细分策略不仅对市场负责人至关重要，而且对製药创新者和临床医生也至关重要。每个部分虽然相互关联，但都面临着独特的挑战和机会，从而塑造了整体市场动态，确保治疗环境能够持续适应并回应患者需求和临床进步。

目录

第 1 章 简介

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 人口老化加剧，出现晕动病症状的风险较高
      • 运动引起的不适感在各年龄层的发生率都有增加
      • 全球旅行和旅游趋势的兴起推动了对有效晕动病治疗解决方案的需求。
    • 限制因素
      • 高昂的开发和製造成本影响了可负担性和盈利
    • 机会
      • 与交通运输和旅游业合作，提供预防晕动病的解决方案
      • 透过基因和生物识别测试实施个人化医疗方法
    • 任务
      • 消费者对新治疗方法疗效的怀疑阻碍了其快速进入市场
  • 市场区隔分析
    • 药物类型：抗胆碱药物对综合晕动病管理和以患者为中心的护理策略的影响日益增强
    • 最终用户：医院在治疗复杂晕动病病例方面发挥的作用越来越大，从而推动了医疗技术的先进。
  • 波特五力分析
  • PESTEL 分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第 6 章 晕动病治疗市场（依治疗类型）

  • 抗胆碱能药物
  • 抗组织胺药

第 7 章 晕动病治疗市场（依治疗类型）

  • 自然疗法
  • 非处方药
  • 处方药

第 8 章 晕动病治疗市场（依剂型划分）

  • 注射
  • 口服
  • 经皮吸收贴片

第九章 晕动病治疗市场（依通路）

  • 网路药局
  • 零售药局

第 10 章 晕动病治疗市场（依最终使用者划分）

  • 诊所
  • 居家护理
  • 医院

第 11 章：美洲晕动病治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

12. 亚太地区晕动病治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

13. 欧洲、中东和非洲晕动病治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十四章 竞争格局

  • 2024 年市场占有率分析
  • FPNV 定位矩阵，2024 年
  • 竞争情境分析
  • 战略分析与建议

公司列表

  • Amneal Pharmaceuticals LLC
  • Astellas Pharma Inc.
  • Baxter International Inc.,
  • Bayer AG
  • BONINE by Wellspring Pharmaceutical Corporation
  • Cipla Limited
  • CVS Health Corporation
  • GlaxoSmithKline plc
  • Lupin Limited
  • Myungmoon Pharma Co. Ltd.
  • Novartis AG
  • Perrigo Company PLC
  • Pfizer Inc.
  • Prestige Consumer Healthcare Inc.,
  • Reliefband Technologies LLC
  • Sanofi SA
  • Taj Pharmaceuticals Limited
  • Teva Pharmaceutical Industries Limited
  • Torrent Pharmaceuticals Ltd
  • WellSpring Pharmaceutical Corporation
Product Code: MRR-A40F58415FBB

The Motion Sickness Treatment Market was valued at USD 719.69 million in 2024 and is projected to grow to USD 740.93 million in 2025, with a CAGR of 3.07%, reaching USD 863.05 million by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 719.69 million
Estimated Year [2025] USD 740.93 million
Forecast Year [2030] USD 863.05 million
CAGR (%) 3.07%

Motion sickness has long been a challenging condition affecting millions globally, and its treatment paradigm is undergoing significant change. The present report offers an in-depth look at the evolving industry, highlighting current therapeutic approaches and emerging trends. As research advances and consumer preferences shift, there is a renewed focus on not only alleviating symptoms but also enhancing overall patient well-being.

This introduction sets the stage for a comprehensive exploration of how innovative treatments, advanced drug formulations, and unique dosage forms are redefining patient care. With a balance of clinical precision and market insight, the content that follows delves into industry transformations, analytical segmentation insights, regional market dynamics, and key corporate strategies. Each segment is meticulously examined to provide industry leaders and decision-makers with a clear, actionable roadmap for navigating this competitive landscape.

This analysis is grounded in rigorous data collection, expert interviews, and contemporary market dynamics, ensuring that readers obtain a holistic overview of both current practices and future directions. By addressing both traditional treatment options and modern innovations, the report encourages stakeholders to consider integrative approaches that span various therapies and distribution channels. In doing so, it ensures that the narrative reflects not just clinical efficacy but also market viability and patient convenience.

Evolving Trends Shaping the Motion Sickness Treatment Market

In recent years, the treatment landscape for motion sickness has experienced transformative shifts. Technological advancements have not only enhanced diagnostic capabilities and wearable sensing devices but have also led to innovative drug delivery systems. These shifts have moved the market away from conventional treatment protocols towards approaches that are more tailored, efficient, and patient-centric.

One of the most notable changes is the increasing integration of digital health technology. Digital therapeutics and real-time monitoring have become integral in assessing patient response to various treatment options, enabling more personalized care strategies. Innovations in pharmacology have resulted in the development of enhanced dosage forms that improve absorption and minimize side effects. In this dynamic climate, conventional interventions are being supplemented-and in some cases replaced-by contemporary therapies that offer significant improvements in safety and efficacy.

Another transformative trend is the evolution in consumer behavior. Informed patients now demand clarity on treatment options, driving companies to innovate and adopt forward-thinking strategies. There is a notable shift towards therapies that embrace natural remedies alongside traditional over-the-counter and prescription medications. Furthermore, market strategies increasingly include strategic partnerships with tech firms to develop apps and monitoring tools, broadening the scope of accessible treatment insights and patient management practices.

This evolving landscape is characterized by a blend of scientific breakthroughs and a market perspective that recognizes the importance of integrated healthcare solutions. As practitioners and investors alike look for sustainable growth avenues, the sector is witnessing a robust interplay between clinical research and market-driven innovation. The drive to incorporate holistic approaches in treatment-encompassing everything from improved drug formulations to advanced delivery channels-underscores the transformative nature of the market today.

The ongoing discourse centers not merely on the efficacy of individual treatments but also on how emerging technologies and innovative business models can collectively define the future of motion sickness management. As regulatory bodies streamline the approval of new products and treatment protocols, the industry finds itself poised for unprecedented levels of collaboration, research, and market penetration.

Comprehensive Segmentation Insights in Motion Sickness Treatment

A critical aspect of understanding the motion sickness treatment market is its complex segmentation. Analysis of the industry reveals that market studies are conducted with considerable nuance, beginning with segmentation based on the type of drugs. This perspective examines treatments centered on anticholinergics and antihistamines, highlighting how each class offers distinct mechanisms for preventing and alleviating symptoms. The nuanced pharmacodynamics of these compounds serve not only as a guideline for clinical practice but also as a marker for future research developments.

Further segmentation exists through the prism of treatment type, where the market is divided among natural remedies, over-the-counter medications, and prescription medications. Such differentiation is crucial as it reflects varied patient needs and regulatory conditions across regions. Natural remedies have gained traction due to perceived safety and minimal side effects, whereas over-the-counter medications underscore accessibility and ease of use. Prescription medications, on the other hand, cater to more severe cases, requiring a balanced approach between potency and safety considerations.

The analysis continues by examining the dosage forms, which are segmented into injectable, oral, and transdermal patches. Each dosage form is associated with specific patient demographics and clinical scenarios. Injectable formulations often cater to acute episodes, while oral medications offer convenience for regular use. Transdermal patches, through sustained release mechanisms, offer the advantage of steady therapeutic levels, embodying a modern approach to drug delivery that maximizes efficacy while minimizing fluctuations in plasma concentration.

Another layer of segmentation focuses on the distribution channel, divided between online pharmacies and retail pharmacies. This segmentation not only reflects evolving consumer buying behaviors but also the growing importance of digital transformation in the pharmaceutical industry. The increasing trust in digital platforms underscores the role of e-commerce in reaching a broader patient base, enabling timely and efficient delivery of therapeutic interventions.

Lastly, segmentation based on the end user-including clinics, home care scenarios, and hospitals-provides a clear picture of the market's multi-dimensional nature. Clinics often serve as centers for initial diagnosis and treatment, while home care solutions offer convenience for chronic or less severe conditions. Hospitals, exemplifying the need for critical and immediate care, often adopt a more structured approach to administration and monitoring. The layered insights offered by these differentiated segments create a comprehensive framework that is critical for strategic planning and market positioning.

Understanding these segmentation strategies is essential not only for market strategists but also for pharmaceutical innovators and clinicians. Each segment, though interconnected, provides unique challenges and opportunities that shape the overall market dynamics, ensuring that the treatment landscape remains adaptable and responsive to both patient needs and clinical advancements.

Based on Type Of Drugs, market is studied across Anticholinergics and Antihistamines.

Based on Treatment Type, market is studied across Natural Remedies, Over-the-Counter Medications, and Prescription Medications.

Based on Dosage Forms, market is studied across Injectable, Oral, and Transdermal Patches.

Based on Distribution Channel, market is studied across Online Pharmacies and Retail Pharmacies.

Based on End User, market is studied across Clinics, Home Care, and Hospitals.

Regional Overview of Global Motion Sickness Treatment Markets

The regional dynamics of the motion sickness treatment market underscore significant variability and growth potential. Market insights indicate that the Americas, a region rich in advanced healthcare infrastructure, continue to be a leader in adopting new treatments and technologies. Here, rising awareness and a strong network of healthcare providers combine with an active pharmaceutical market, driving innovation and investment in both traditional and novel treatment methods.

In contrast, the Europe, Middle East & Africa region presents a unique mix of opportunities and challenges driven by differing regulatory landscapes and varying levels of technological adoption. Regulatory frameworks in Europe promote rigorous clinical testing and approval processes, ensuring that technological innovations meet high safety standards. Meanwhile, regions within the Middle East and Africa are witnessing increased investment in healthcare infrastructure, fostering an environment ripe for adopting advanced therapeutic approaches. Such variation necessitates adaptable strategies that cater to local market dynamics while aligning with global best practices.

The Asia-Pacific region, with its robust manufacturing capabilities and rapidly growing consumer base, is emerging as a critical market for motion sickness treatment. The region's dynamic growth is backed by a combination of traditional medical practices and modern pharmaceutical advancements. This dual approach is particularly beneficial in addressing both acute and chronic conditions of motion sickness, thereby contributing to a balanced market portfolio that spans from innovative drug formulations to traditional over-the-counter solutions.

Cross-regional analysis reveals that while each region faces its unique set of challenges-ranging from regulatory hurdles to cultural preferences-the overarching trends indicate an increasing harmonization of treatment protocols and market practices. Global connectivity has paved the way for shared innovations, with pharmaceutical research increasingly drawing on insights from diverse geographical areas. Such a synthesis of regional strengths not only enhances the overall quality of motion sickness treatment but also fosters an environment of collaboration between emerging and established markets.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Corporate Key Players Shaping the Motion Sickness Treatment Market

A review of key companies reveals a competitive environment where major players are driving change through innovation, strategic partnerships, and robust market positioning. Amneal Pharmaceuticals LLC and Astellas Pharma Inc. are renowned for their commitment to research and for offering effective anticholinergic and antihistaminic formulations that align with the unique needs of their patient bases. Baxter International Inc. and Bayer AG, with their extensive portfolio of over-the-counter products, have remained at the forefront of delivering accessible solutions that are widely trusted by consumers.

BONINE by Wellspring Pharmaceutical Corporation and Cipla Limited have further expanded the market by investing in advanced dosage forms and adopting rigorous quality control measures. CVS Health Corporation and GlaxoSmithKline plc have emerged as leaders in integrating digital health solutions into their distribution channels, thereby providing a seamless purchase experience for patients. Companies such as Lupin Limited and Myungmoon Pharma Co. Ltd. are recognized for their innovative approaches to prescription medications, offering alternatives that combine traditional pharmaceutical excellence with modern therapeutic benefits.

Novartis AG and Perrigo Company PLC are known for their targeted investments in research and development, focusing on the creation of new dosage forms like transdermal patches and sophisticated oral formulations that enhance patient compliance. Pfizer Inc. and Prestige Consumer Healthcare Inc. continue to leverage their global networks to drive market penetration, securing significant market shares through strategic collaborations. Reliefband Technologies LLC has carved a niche by introducing wearable solutions that complement pharmacological interventions, while Sanofi S.A. champions next-generation therapies that address the entire spectrum of motion sickness.

Taj Pharmaceuticals Limited, Teva Pharmaceutical Industries Limited, Torrent Pharmaceuticals Ltd, and WellSpring Pharmaceutical Corporation round out the list of key companies, each contributing uniquely to the dynamic market environment. Their combined efforts in research, innovation, and market expansion have fostered an ecosystem that nurtures continuous growth and resilience. These companies' commitment to clinical excellence and market adaptability underscores a broader industry trend focused on leveraging innovation to meet fluctuating consumer demands and stringent regulatory requirements.

Together, these industry leaders form a mosaic of expertise that spans global regions and a wide range of therapeutic needs. Their concerted efforts not only underscore the competitive spirit of the market but also highlight the collaborative potential that drives continuous improvement in motion sickness treatment.

The report delves into recent significant developments in the Motion Sickness Treatment Market, highlighting leading vendors and their innovative profiles. These include Amneal Pharmaceuticals LLC, Astellas Pharma Inc., Baxter International Inc.,, Bayer AG, BONINE by Wellspring Pharmaceutical Corporation, Cipla Limited, CVS Health Corporation, GlaxoSmithKline plc, Lupin Limited, Myungmoon Pharma Co. Ltd., Novartis AG, Perrigo Company PLC, Pfizer Inc., Prestige Consumer Healthcare Inc.,, Reliefband Technologies LLC, Sanofi S.A., Taj Pharmaceuticals Limited, Teva Pharmaceutical Industries Limited, Torrent Pharmaceuticals Ltd, and WellSpring Pharmaceutical Corporation. Strategic Recommendations for Advancing Motion Sickness Treatment Innovation

Industry leaders are encouraged to adopt a multi-faceted strategy to maintain competitive advantage and pioneer future innovations in motion sickness treatment. First, it is imperative to invest heavily in research and development to identify new therapeutic compounds that offer increased efficacy with reduced side effects. Strengthening R&D will catalyze the discovery of novel drug delivery systems-particularly in improving the bioavailability of both natural and synthetic remedies-thus ensuring treatments remain at the cutting edge of medical science.

Leveraging digital transformation is another key action point. Implementing advanced digital monitoring tools and integrating telemedicine solutions can greatly enhance patient management. Such digital strategies not only facilitate real-time data collection but also enable personalized treatment approaches that adjust to individual patient needs. As a result, companies can optimize therapy outcomes while ensuring a seamless patient experience.

Furthermore, fostering robust partnerships is essential. Collaborative efforts with technology companies, regulatory bodies, and academic institutions can unlock new insights that drive product innovation and market expansion. Strategic alliances can expedite the clinical trial processes and streamline regulatory approvals, offering companies a competitive edge in bringing next-generation therapies to market.

The importance of diversifying product portfolios cannot be overstated. Expanding offerings to include a range of dosage forms-such as injectables, oral medications, and transdermal patches-appears critical in catering to various clinical profiles and patient preferences. With an eye on market segmentation insights, companies should adapt their products to fit diverse distribution channels, whether via digital commerce or traditional retail pharmacies, enhancing overall market penetration.

Additionally, focusing on geographic diversification is recommended. Tailoring strategies to meet the unique regulatory and cultural needs of key regions such as the Americas, Europe, Middle East & Africa, and Asia-Pacific will help in maximizing market share. This might include localized clinical studies, region-specific marketing campaigns, and adaptations of product formulations to meet local consumer demands.

Lastly, industry leaders should continually monitor emerging trends and regulatory shifts. Staying abreast with global best practices and anticipating market disruptions through proactive policy alignment can provide significant strategic benefits. In an industry that is characterized by rapid innovation and stringent compliance requirements, a forward-thinking approach that marries clinical excellence with technological integration and strategic market positioning will prove indispensable.

Conclusion: Future Trajectories in Motion Sickness Treatment

Through rigorous analysis and detailed market segmentation, it becomes evident that the motion sickness treatment market is on the cusp of substantial evolution. The convergence of advanced pharmaceutical research, digital transformation, and strategic industry collaborations has created an environment ripe for innovative breakthroughs. Key insights reveal that from drug type classifications and treatment modality considerations to nuanced segmentation based on dosage forms, distribution channels, and end users, every facet of the market is interlinked with both clinical efficiency and market dynamics.

As treatment strategies are refined and tailored to specific patient needs, it is clear that future progress depends on a balanced approach that integrates both legacy therapies and modern innovations. The regional disparities and opportunities across the Americas, Europe, Middle East & Africa, and Asia-Pacific underscore the importance of a global perspective in developing comprehensive treatment protocols. Moreover, major industry players continue to push the envelope through rigorous R&D, strategic partnerships, and adaptive market strategies that cater to ever-evolving consumer demands.

This convergence of clinical rigor and market responsiveness is not only setting new benchmarks for treatment efficacy but is also reshaping the broader healthcare landscape. The continuous collaboration between researchers, healthcare providers, and industry leaders is essential for driving forward a new era of motion sickness management, one that is rooted in both scientific integrity and commercial dynamism. In essence, the motion sickness treatment landscape of tomorrow promises to be more integrated, patient-centric, and innovation-driven than ever before.

The insights summarized herein serve as a call for sustained investment, strategic foresight, and collaborative synergy, underscoring the need for stakeholders to not only respond to current trends but also anticipate future challenges. The future trajectory of this market, buoyed by technological and pharmaceutical innovations, signals robust growth and enhanced patient outcomes, marking an exciting era for all industry participants.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing aging population with a higher risk of developing motion sickness symptoms
      • 5.1.1.2. Rising prevalence of motion-induced discomfort among diverse age groups
      • 5.1.1.3. Growing global travel and tourism trends led to demand for effective motion sickness treatment solutions
    • 5.1.2. Restraints
      • 5.1.2.1. High development and manufacturing costs impacting affordability and profitability
    • 5.1.3. Opportunities
      • 5.1.3.1. Collaborating with transportation and tourism sectors to provide preventative motion sickness solutions
      • 5.1.3.2. Implementing personalized medicine approaches through genetic and biometric testing
    • 5.1.4. Challenges
      • 5.1.4.1. Consumer skepticism regarding the efficacy of emerging treatments hampers rapid market acceptance
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type Of Drugs: Rising impact of anticholinergics on comprehensive motion sickness management and patient-centric care strategies
    • 5.2.2. End User: Increasing role of hospitals in addressing complex motion sickness cases led to advanced medical technologies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Motion Sickness Treatment Market, by Type Of Drugs

  • 6.1. Introduction
  • 6.2. Anticholinergics
  • 6.3. Antihistamines

7. Motion Sickness Treatment Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Natural Remedies
  • 7.3. Over-the-Counter Medications
  • 7.4. Prescription Medications

8. Motion Sickness Treatment Market, by Dosage Forms

  • 8.1. Introduction
  • 8.2. Injectable
  • 8.3. Oral
  • 8.4. Transdermal Patches

9. Motion Sickness Treatment Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Online Pharmacies
  • 9.3. Retail Pharmacies

10. Motion Sickness Treatment Market, by End User

  • 10.1. Introduction
  • 10.2. Clinics
  • 10.3. Home Care
  • 10.4. Hospitals

11. Americas Motion Sickness Treatment Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Motion Sickness Treatment Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Motion Sickness Treatment Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Amazon transforms healthcare delivery by integrating virtual consultations with upfront pay-per-visit pricing
    • 14.3.2. Panav Biotech launches FDA-approved Maropitine Injection to enhance pet care
    • 14.3.3. Zydus Lifesciences secures USFDA approval for its scopolamine transdermal system to transform motion sickness treatment
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amneal Pharmaceuticals LLC
  • 2. Astellas Pharma Inc.
  • 3. Baxter International Inc.,
  • 4. Bayer AG
  • 5. BONINE by Wellspring Pharmaceutical Corporation
  • 6. Cipla Limited
  • 7. CVS Health Corporation
  • 8. GlaxoSmithKline plc
  • 9. Lupin Limited
  • 10. Myungmoon Pharma Co. Ltd.
  • 11. Novartis AG
  • 12. Perrigo Company PLC
  • 13. Pfizer Inc.
  • 14. Prestige Consumer Healthcare Inc.,
  • 15. Reliefband Technologies LLC
  • 16. Sanofi S.A.
  • 17. Taj Pharmaceuticals Limited
  • 18. Teva Pharmaceutical Industries Limited
  • 19. Torrent Pharmaceuticals Ltd
  • 20. WellSpring Pharmaceutical Corporation

LIST OF FIGURES

  • FIGURE 1. MOTION SICKNESS TREATMENT MARKET MULTI-CURRENCY
  • FIGURE 2. MOTION SICKNESS TREATMENT MARKET MULTI-LANGUAGE
  • FIGURE 3. MOTION SICKNESS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 4. MOTION SICKNESS TREATMENT MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS MOTION SICKNESS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. AMERICAS MOTION SICKNESS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES MOTION SICKNESS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 21. UNITED STATES MOTION SICKNESS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA MOTION SICKNESS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA MOTION SICKNESS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. MOTION SICKNESS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 27. MOTION SICKNESS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MOTION SICKNESS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MOTION SICKNESS TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY NATURAL REMEDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY OVER-THE-COUNTER MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY PRESCRIPTION MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY TRANSDERMAL PATCHES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS MOTION SICKNESS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES MOTION SICKNESS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA MOTION SICKNESS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 234. MOTION SICKNESS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 235. MOTION SICKNESS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024